Matrix Metalloproteinase-9 Level and Gene Polymorphism in Sleep Disordered Breathing Patients with or without Cardiovascular Disorders

Abstract

Objective: Obstructive sleep apnea syndrome (OSAS) is associated with increased cardiovascular morbidity and mortality. We aimed to investigate the matrix metalloproteinase-9 (MMP-9) level and MMP-9 gene polymorphism in sleep apnea patients with or without cardiovascular disease. Study Design: Case-control study. Material and Methods: Two hundred nine patients [Mean age (±SD), 47 (±12) yrs; M/F, 170/39] diagnosed with sleep-disordered breathing were included in the study. Serum MMP-9 level was performed using enzyme-linked immunosorbant assay (ELISA) and MMP-9 gene polymorphism with polymerase chain reaction-restriction fragment length polymorphism. We divided the patient group into two subgroups: (1) patients with confirmed cardiovascular disease, i.e. CV-P Group and (2) patients without cardiovascular disease, CV-N Group. We compared all parameters between the two groups. Results: There were 56 OSAS patients with cardiovascular disorder (CV-positive group) and 153 OSAS patients without cardiovascular disorder (CVnegative group). CC, CT and TT genotype distributions between groups were similar [31 (55%), 25 (45%), 0 (0%) vs 88 (57%), 61 (40%), 4 (3%); respectively, p>0.05]. MMP-9 level was significantly higher in CV-P patients (442.7±139.3 pg/mL) than in CV-N patients (364.4±165.0 pg/mL; p=0.0018). Conclusion: Our results showed that the presence of MMP-9 polymorphism was not associated with cardiovascular disease. MMP-9 level was higher in OSAS patients with cardiovascular disorders than without cardiovascular disorders. Finally, MMP-9 genotype was not associated with serum MMP-9 levels. Turkish Başlık: Kardiyovasküler Hastalığı olan ve olmayan Obstrüktif Uyku Apne Sendromlu Hastalarda Matriks Metalloproteinaz-9 Aktivitesi ile Gen Polimorfizmi Anahtar Kelimeler: Kardiyovasküler hastalıkları, MMP-9, polimorfizm, uyku apnesi, hipertansiyon Amaç: Obstrüktif uyku apne sendromu (OUAS) artmış kardiyovasküler morbidite ve mortalite ile ilişkilidir. Bu çalışmada kardiyovasküler hastalığı olan ve olmayan uyku apneli hastalarda matriks metalloproteinaz-9 (MMP-9) düzeyi ile MMP-9 gen polimorfizminin araştırılması amaçlandı. Gereç ve Yöntemler: Uykuda solunum bozukluğu teşhisi almış 209 hasta [Ortalama yaş (±SS), 47 (±12) yıl; E/K, 170/39] çalışmaya dahil edildi. Serum MMP-9 düzeyi ELISA, MMP-9 gen polimorfizmi polimeraz zincir reaksiyonu ve restriksiyon fragmanı uzunluk polimorfizmi ile DNA örneklerinde belirlendi. Hastalar kardiyovasküler hastalığı olan, KV-P grubu ve kardiyovasküler hastalığı olmayan, KV-N grubu olmak üzere iki alt gruba ayrıldı. Bulgular: Kardiyovasküler hastalığı olan (KV-P grup) 56 ve kardiyovasküler hastalığı olmayan (KV-N grup) 153 OUAS hasta tesbit edildi. Gruplar arası CC, CT ve TT genotip dağılımı benzer [31 (55%), 25 (45%), 0 (0%) vs 88 (57%), 61 (40%), 4 (3%); sırasıyla, p>0.05] tesbit edildi. MMP-9 düzeyi KV-P hastalarda (442.7±139.3 pg/mL) KV-N hastalara (364.4±165.0 pg/mL) göre anlamlı (p=0.0018) yüksek saptandı. Sonuç: Bulgularımız, MMP-9 polimorfizm varlığının kardiyovasküler hastalıklarla ilişkili olmadığını gösterdi. MMP-9 düzeyi kardiyovasküler hastalığı olan OUAS'lı hastalarda kardiyovasküler hastalığı olmayanlara göre yüksek saptandı. Sonuç olarak, MMP-9 genotipi serum MMP-9 düzeyi ile ilişkili bulunmadı.

Keywords

• Cardiovascular disease, MMP-9, polymorphism, sleep apnea, hypertension

Matrix Metalloproteinase-9 Level and Gene Polymorphism in Sleep Disordered Breathing Patients with or without Cardiovascular Disorders

Öz

Kaynakça

1. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:19-25.
2. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep-apnea: a 7-year follow up. Am J Respir Crit Care Med 2002;166:159-65. [CrossRef]
3. Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 2001;164:2147-65.
4. Brauer PR. MMPs role in cardiovascular development and disease. Front Biosci 2006;11:447-78. [CrossRef]
5. Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Regulations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004;109:2850-6. [CrossRef]
6. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006;69:636-45. [CrossRef]
7. Wang L, Zhu T, Li Y. Relationship between matrix metalloproteinase-9 polymorphism and acute coronary syndrome. Journal of Nanjing Medical University 2007;21:147-50. [CrossRef]
8. Tazaki T, Minoguchi K, Yokoe T, Samson KT, Minoguchi H, Tanaka A, et al. Increased levels and activity of matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2011;170:1354-9. [CrossRef]

9. Ye J, Liu H, Li Y, Liu X, Zhu J. Increased serum levels of C-reactive protein and matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Chin Med J 2007;120:1482-6.
10. Demacq C, de Souza AP, Machado AA, Gerlach RF, Tanus-Santos JE. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 2005;365:183-7. [CrossRef]
11. The Report of American Academy of Sleep Medicine. Task Force Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999;5:667-89.
12. Rechtschaffen A, Kales A (1968). A Manual of Standardized Terminology, Technique, and Scoring System for Sleep Stages of Human Subjects, BIS/ BRI, UCLA, Los Angeles.
13. Öztürk L, Mansour B, Yüksel M, Yalçın AS, Çelikoğlu F, Gökhan N. Lipid peroxidation and osmotic fragility of red blood cells in sleep apnea patient. Clin Chim Acta 2003;332:83-8. [CrossRef]
14. Gremlich S, Nguyen D, Reymondin D, Hohlfeld P, Vial Y, Witkin SS, et al. Fetal MMP2/MMP9 polymorphisms and intrauterine growth restriction risk. J Reprod Immunol 2007;74:143-51. [CrossRef]
15. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner D, et al. Plasma concentration and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85. [CrossRef]
16. Kaditis AG, Alexopoulos EI, Karathanasi A, Ntamagka G, Oikonomidi S, Kiropoulos TS, et al. Adiposity and low grade systemic inflammation modulate matrix metalloproteinase-9 levels in Greek children with sleep apnea. Pediatr Pulmonol 2010;45:693-9. [CrossRef]
17. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-94. [CrossRef]
18. Opstad TB, Pettersen AAR, Weiss TW, Akra S, Ovstebo R, Arnesen H, et al. Genetic variation, gene expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta 2012;413:113-20. [CrossRef] Alp E, Menevse S, Tulmac M, Kan D, Yalcin R, Erkan AF, et al. Lack of association between matrix metalloproteinase-9 and endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in Turkish population. DNA Cell Biol 2009;28:343-50. [CrossRef]
19. Pöllanen PJ, Karhunen PJ, Mikkelsson J, Laippala P, Perola M, Penttila AM, et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: An autopsy study. Arterioscler Thromb Vasc Biol 2001;21:1446-50. [CrossRef]
20. Volna J, Kemlink D, Kalousova M, Vavrova J, Majerova V, Mestek O, et al. Biochemical oxidative stress-related markers in patients with obstructive sleep apnea. Med Sci Monit 2011;17:CR491-7. [CrossRef]
21. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313-6. [CrossRef]
22. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996;157:4159-65. 2012; 30: 8-12